Cadre Holdings, Inc. quarterly report, Q3 FY2022

Cadre Holdings, Inc. — Q3 2022 Form 10-Q

Reporting period: Three and nine months ended September 30, 2022. Unaudited results; amounts below are in millions except per-share data and percentages. Cadre manufactures and distributes safety and survivability products, including body armor, duty gear and explosive ordnance disposal equipment.

Financial performance

MetricQ3 2022Q3 20219M 20229M 2021
Net sales$111.6$98.7$334.2$323.8
Gross profit / margin$43.7 / 39.2%$39.3 / 39.8%$127.2 / 38.1%$131.5 / 40.6%
Operating income / margin$10.3 / 9.2%$11.5 / 11.7%$4.0 / 1.2%$42.4 / 13.1%
Net income (loss)$4.9($5.3)($0.8)$8.4
EPS, basic and diluted$0.13($0.19)($0.02)$0.30
Adjusted EBITDA (non-GAAP)$20.7$15.4$53.3$56.1

Q3 sales rose 13.1%, supported by acquisitions, armor volume and agency demand for hard goods. Nine-month sales increased 3.2%; acquisitions and armor demand were partly offset by prior-year large armor, duty gear and crowd-control orders. Nine-month gross margin fell to 38.1%, reflecting acquisition-related inventory step-up amortization and unfavorable product mix, while pricing partly offset material inflation. Distribution margin also weakened on a greater agency-versus-retail sales mix.

Q3 net income improved year over year partly because the 2021 comparison included a $15.2 million debt-extinguishment loss. For nine months, operating income fell 90.6% and net income turned to a loss. Management attributed the deterioration principally to unfavorable product and portfolio mix and $29.4 million of stock-based compensation expense. The compensation expense included a $22.1 million charge upon modification of an executive incentive plan.

Cash flow, liquidity and debt

  • Nine-month operating cash flow was $29.5 million, versus $31.0 million a year earlier. It included a $29.0 million noncash stock-compensation add-back; accounts receivable, inventory and payables/other liabilities were cash uses.
  • Investing cash outflow was $58.0 million, including $55.0 million net cash paid for the Radar and Cyalume acquisitions and $2.9 million for capital expenditures. Financing cash inflow was $31.2 million, principally from the secondary offering.
  • Cash was $36.4 million at September 30, 2022. Total debt, net of discounts and issuance costs, was approximately $153.1 million, down from $159.7 million at year-end 2021. No borrowings were outstanding on the $100 million revolving facility; availability was $97.7 million after letters of credit.
  • Current assets were $187.8 million and current liabilities $74.4 million. The term loan matures in 2026 and bears floating-rate exposure; a $100 million interest-rate swap hedges a portion. Credit covenants include a minimum fixed-charge coverage ratio of 1.25:1 and a maximum leverage ratio of 3.75:1 through Q3 2022, stepping down to 3.50:1 thereafter.
  • Management stated that cash, operating cash flows and available borrowing capacity should meet liquidity needs for at least 12 months following the filing.

Material changes and other notable items

  • Cadre acquired Radar in January for $19.4 million and Cyalume in May for $35.7 million, net of cash acquired. Purchase-price allocations remained preliminary. Reported goodwill rose to $77.2 million, and inventory increased to $79.2 million from $64.0 million at year-end.
  • The company completed a primary share issuance in two tranches, receiving approximately $53.4 million in net proceeds. Shares issued and outstanding increased from 34.4 million at year-end to 37.3 million at September 30.
  • Orders backlog was $125.2 million, up from $113.8 million at December 31, 2021. Management said the increase reflected acquisitions, armor demand and large government less-lethal orders, partly offset by shipments of large international bomb-suit and contractual armor orders. Some backlog orders depend on budget appropriations or may be canceled.
  • No specific earnings or sales guidance was provided. Management cited supply-chain disruption and delays, inflation in materials, labor and shipping, foreign-currency losses, and potential delivery delays as risks.
  • A DOJ investigation concerns allegations about labeling of soft-body-armor vest accessory panels; the company said it could not yet assess the merits or potential exposure. A $7.5 million product-liability jury verdict was on appeal, with oral argument held October 25, 2022; management considered a loss reasonably possible but not probable and said applicable insurance would indemnify losses. The filing also describes a prior FTC consent order and ongoing compliance obligations.
  • Cadre paid $1.0 million to a company controlled by its CEO for Cyalume acquisition services and $2.0 million for secondary-offering services. Management reported disclosure controls were effective; integration of acquired companies’ financial controls was ongoing.

Important facts for investors to verify

  • How much of the Q3 and year-to-date sales growth is organic versus attributable to Radar and Cyalume, and whether backlog converts to sales on expected timing.
  • Whether margin pressure, acquisition inventory step-up costs and elevated operating expenses persist; review results excluding the unusually large stock-based compensation charge as well as GAAP results.
  • Debt covenant headroom, floating-rate borrowing costs, and the effect of interest-rate changes beyond the portion hedged by the swap.
  • Final acquisition purchase-price allocations, acquired-company integration, and any further acquisition-related costs or working-capital needs.
  • Developments in the DOJ investigation and product-liability appeal, including insurance coverage and any potential exposure not covered by insurance.
  • The durability of cash generation and liquidity given working-capital needs, planned investment, dividends and the company’s stated reliance on available credit capacity.